Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates
Publication information:
Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clinical Cancer Research. 2024;30(7):1281–1292.